Related Experiment Video

Updated: Dec 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy

Han Gong1, Dan Nie2, Zhengyu Li1

  • 1Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, 610041, China.

Current Cancer Drug Targets
|August 19, 2020
PubMed

Insights

Understanding the six hallmarks of cancer and molecular alterations is key to developing new ovarian cancer treatments. Novel drug targets and combination strategies show promise for improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer cells acquire capabilities like self-sufficiency in growth signals and insensitivity to anti-growth signals, known as the six hallmarks of cancer.
  • Genetic and protein alterations drive these hallmarks, crucial for understanding cancer development and treatment.

Purpose of the Study:

  • To provide a comprehensive overview of molecular alterations in ovarian cancer carcinogenesis.
  • To discuss emerging biological agents and combination strategies targeting aberrant pathways for ovarian cancer treatment.

Main Methods:

  • Review of genetic and protein alterations involved in cancer development.
  • Analysis of targeted therapeutic strategies and clinical trial data for ovarian cancer.
  • Exploration of novel drug targets and combination therapies.

Main Results:

  • Targeted agents like PARP, MEK, VEGF, and Chk1/Chk2 inhibitors show improved progression-free survival in specific ovarian cancer subtypes.
  • Current targeted therapies have limitations in overall survival benefits and are restricted to specific molecular subtypes.

Conclusions:

  • Further research into novel drug targets and combination strategies is essential for improving ovarian cancer treatment outcomes.
  • Targeting aberrant molecular pathways holds promise for future therapeutic advancements in ovarian cancer.
Keywords:
MEKOvarian cancerPARPVEGFcancer hallmarktargeted therapy

More Related Videos

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

14.1K
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K